【4565】そーせいG 449 【SOSEI第28回定時株主総会：6/22、株式分割：6/30】
■ このスレッドは過去ログ倉庫に格納されています
>>70
こいつが一回でネガキャン終わるわけない
IPに気付かずうっかり書き込んじゃったんじゃね？ｗ
ルサンチメンズｗ ※SOSEI：役員の異動に関するお知らせ。(6/4)
・辞任する執行役：Andrew Oakley（アンドリュー・オークリー）執行役副社長CFO
・辞任日：2018年6月4日
・辞任の理由：一身上の都合によるもの
・・・
↓
※Autolus Therapeutics: Autolus announces appointment of Andrew J. Oakley as Senior Vice President and Chief Financial Officer. (6/8)
London, 8 June 2018 - Autolus Therapeutics Limited, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies,
today announced the appointment of Andrew J. Oakley as its Senior Vice President and Chief Financial Officer, effective prior to the closing of Autolus’ planned initial public offering.
Dr. Christian Itin, Autolus’ Chairman and Chief Executive Officer, commented:
“We are delighted to welcome Andrew to Autolus. Andrew brings a wealth of international finance experience to Autolus, having been a CFO for public life science companies for more than 15 years.
His proven ability to successfully manage growth is an excellent fit for Autolus and our drive to unlock the potential of T cell therapies in oncology.”
Andrew Oakley said:
“I am excited to join Autolus as Senior Vice President and Chief Financial Officer at this transformational stage in the company’s development.
Autolus aims to be a leading global programmed T cell therapy company and I look forward to working with my new colleagues as we progress our programmed T cell therapies through development and towards commercialisation.”
Andrew joins Autolus from Sosei Group Corporation where he served as its executive vice president and chief financial officer since February 2017.
Prior to that, he served as chief financial officer, company secretary and executive board member of Vectura Group plc from January 2015 to June 2016,
as chief financial officer of NovImmune SA from March 2014 to November 2014 and as executive vice president and chief financial officer of Actelion Pharmaceuticals Ltd from January 2003 to August 2013.
He has also held a senior finance role at Accenture, executive leadership positions in major multinational building material companies, and has spent several years as an equity analyst with banks in Australia, the United Kingdom and the United States.
Andrew holds a Bachelor of Economics degree from Macquarie University and an MBA from London Business School and has been a Member of the Australian Institute of Chartered Accountants since 1987. ↓
※BioCentury: Autolus proposes IPO terms. (6/11)
06/11/2018 | 04:42am
Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ.
In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing one ordinary share.
At the $16 midpoint, Autolus would raise $125 million and would be valued at $604.4 million.
Underwriters are Goldman Sachs, Jefferies, Wells Fargo and William Blair.
Autolus' pipeline includes four programmed T cell therapies in clinical testing to treat several blood cancers and neuroblastoma.
The most advanced, AUTO1, consists of CAR T cells targeting CD19, and is in Phase I testing to treat adults with acute lymphoblastic leukemia (ALL).
The company's AUTO2 is in a Phase I/II trial to treat multiple myeloma.
It is a CAR T therapy targeting BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) and transmembrane activator and CAML interactor (TACI).
Autolus' AUTO3, a CAR T therapy targeting CD19 and CD22, is in a pair of Phase I/II studies to treat diffuse large B cell lymphoma and pediatric ALL.
A fourth candidate targeting ganglioside GD2 (GD2), AUTO6, is in a Phase I study conducted by Cancer Research UK to treat neuroblastoma; the biotech hopes to begin clinical studies in 2020 of a next-generation version of that candidate.
In mid-2018, Autolus intends to start a Phase I/II trial of AUTO4, a CAR targeting T cell receptor beta constant 1 (TRBC1) to treat peripheral T cell lymphoma.
The company has raised $176.4 million in equity funding to date.
Its largest shareholder is Syncona Ltd. with 41%, followed by Woodford Investment Management with 26% and Arix Bioscience plc with 9%.
Autolus raised $80 million in a series C round in September (see BioCentury, Sept. 29, 2017).
Also on Friday, Autolus named Andrew Oakley SVP and CFO, effective prior to the IPO's closing.
He was EVP and CFO of Sosei Group Corp. (Tokyo:4565).
Oakley has also been CFO of Vectura Group plc, NovImmune S.A. (Plan-les-Ouates, Switzerland) and Actelion Ltd., which Johnson & Johnson acquired. 結局pluristemには金出すことにしたの？やめたの？
マジでこの会社はなんのアナウンスもしないな まあcvcのために集めた50億円も食い尽くしていくんじゃないか？ 株価以外に悪材料がなさ過ぎる
売り煽りも期間の空売り以外のネタ出せないし ＤＬＢって市場で買うとなるといくらぐらいなんだろう？
５０％の確率で、毎年数百億円が入ってくる権利なら
１兆円ぐらいで共同で購入してもよさげだな まあ、２４年まで赤字と予想するアナリストがいてもこの株価
赤字以下は無いから２０年の黒字サプライズでもあれば楽しみだね
相場は過去に学べ
ヘプと同規模買収で再び大相場になるかもね ・・・
※MRC LMB: Congratulations to Richard Henderson from MRC_LMB on being made a Companion of Honour in the Queen’s Birthday Honours. (6/8)
※BBC NEWS: Nobel laureate joins another exclusive club. (6/8)
※Heptares: Congratulations to our founder Richard Henderson, named a Companion of Honour in the Queen's Birthday Honours list. (6/8)
※Varsity Cambridge: Three Cambridge academics recognised in 2018 Queen’s Birthday Honours List. (6/9)
↓
※MRC Laboratory of Molecular Biology (MRC LMB): Richard Henderson made Companion of Honour. (6/11)
Published today at 10:09 am
Richard Henderson, from the LMB’s Structural Studies Division, has been made a Companion of Honour in the Queen’s 2018 Birthday Honours list, for services to electron microscopy of biological molecules.
The Order of the Companions of Honour was founded in 1917 by King George V and is awarded for a major contribution to the arts, science, medicine, or government lasting over a long period of time.
The Order consists of the Sovereign and a maximum of 65 members.
Membership confers no title, but those inducted into the Order are entitled to use the post-nominal letters CH.
Richard is a structural biologist, with a physics background.
He has been at the LMB since 1966, when he started as a Ph.D. student in Structural Studies with David Blow.
He was joint Head of the Structural Studies Division from 1986-2000, and then LMB Director from 1996-2006.
For the last 20 years, he has been working to improve the methodology of single particle electron cryomicroscopy (cryoEM),
which has recently reached the stage where it is possible to obtain atomic structures of a wide variety of macromolecular complexes routinely without crystals.
In addition, he helped to develop the method of “conformational thermostabilisation” that allows any membrane protein to be made more stable while at the same time retaining a chosen conformation of interest.
This helped the crystallisation and structure determination of several G protein-coupled receptors (GPCRs).
With help from MRCT, now LifeArc, this led to the founding of the MRC start-up company Heptares in 2007.
Heptares now has ~125 employees and is wholly owned by the Japanese company Sosei, developing new drugs for medically important GPCRs.
During his career Richard has actively supported science across the UK and the rest of the world, including being a member of the MRC Council from 2008-2014.
He has been recognised many times for his work, including being elected a Fellow of The Royal Society in 1983.
Most recently Richard shared the Nobel Prize for Chemistry in 2017 for developing cryo-electron microscopy for the high-resolution structure determination of biomolecules in solution.
Richard commented “It is a great honour to be named as a Companion of Honour, following in the footsteps of other LMB scientists and my undergraduate teacher from Edinburgh, Peter Higgs.”
Previous members of the LMB bestowed with the honour include Sydney Brenner, Max Perutz, Fred Sanger, Cesar Milstein and John Sulston. >>110
嘘つきで糞みたいな経営陣よりよっぽど信用出来るわwww >>116
んな株に執着するお前は何なの？
派遣マンみたいに損させられてるのか？ 株は信用度で買うんじゃないからな
あくまでも現株価が将来像より安いかだ
整合性のある具体的な噓言が一つもあがっていないわけだが
株価が上がれば方針転換なんてしなければならないものだし
そんなに信じられないなら不祥事のＭ銀でも買えばいいじゃない 信用はしてないけど、3000万が1300万になってもうて、さすがに萎えております
人生やるせないな。 【※注目※】最短翌日に仮想通貨を受け取れます！
一般的に仮想通貨で 稼ぐ方法としては、、、
◆仮想通貨トレード
◆マイニング
◆ＩＣＯ
◆アービトラージ
◆ネットワークビジネス
などで稼ぐ方法が有名ですね。
ですが、今回は全く今までとは違った 稼ぎ方を教えてくれるみたいなのでチェックして下さいね＾＾
▼早速、最新の稼ぎ方をチェックする▼
http://lr-asp.com/lp/19610/874859
今回の情報は仮想通貨を買って トレードをするとか、 ビットコインを買ってＩＣＯに投資する、、、
といった類の情報ではありません。
「あなたが１円も使うことなく価値ある仮想通貨を何度も稼ぎ出す」といったコンセプトの今までにない驚きの情報です。 こんな方法があったのかという感じです。(全て動画で明らかになってます)
もちろん実際にどれくらいの人が稼いでいるかの実積動画も公開されています。この動画にはあの情報ライブミヤネ屋で「人生変わりました！ビットコインで 」という名言を残したあの有名な激カワ現役女子大生も登場してるので楽しみに見てくださいね♪
最短で明日には受け取ることも出来るようです！！
しかも、将来値上がることが期待大の上場確定のコインも受け取れるというメリットが非常に大きい情報です。少しでも興味のある方はこちらから
http://lr-asp.com/lp/19610/874859
すぐに行動をすることによって稼げるチャンスを早めることが出来ます。毎月５０万円や１００万円といった大きなキャピタルゲインを得ることが出来るようなので是非チェックしてみて下さいね＾＾ ※The IPKat: Kymouse's stay of execution. (6/11)
Rose Hughes Monday, June 11, 2018
Earlier this year, this Kat reported on the UK Court of Appeal decision that Regeneron's patent EP1360287, and its divisional EP2264163, were sufficient and infringed by Kymab.
The Regeneron vs Kymab dispute concerns highly valuable platform technologies for antibody therapeutics.
Following continued disagreement between the parties, the Court of Appeal has now issued its judgment on the form of order.
The court ordered a final injunction restraining Kymab from infringing the patents and delivery up and destruction of products produced by the claimed methods, including relevant antibodies and antibody producing cells.
Kymab, in turn, was granted a stay of the injunction pending an application to appeal to the Supreme Court (and if permission is granted, the appeal).
In arriving at his decision, Lord Justice Kitchin considered the potential impact of the Form of Order not only on the parties but also on the development of clinically significant therapeutics.
Kymab's research:
Since publication of its Kymouse platform in 2014, Kymab has significantly invested in the use of the technology for research and development in a range of disease areas, in collaboration with a number of partners.
In 2016, Kymab, in collaboration with The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI), published the use of Kymouse antibodies to produce antibodies targeting HIV-1.
The methods used HK and HKL Kymouse strains (products to which the infringement action relates).
Kymab subsequently received a $9m grant from the Bill & Melinda Gates Foundation for research and development of immunotherapies and vaccines for infectious disease.
Kymab indicates that in their infectious disease pipeline, they have active programmes for malaria, thyphoid fever, HIV and whooping cough.
Kymab is also currently collaborating with Heptares, a UK based drug discovery company specializing in drugs targeting the G-protein coupled receptor (GPCR) super-family.
In 2016, Kymab announced a partnership with Heptares for research, development and commercialization of immuno-oncology therapeutics targeting GPCRs.
According to the Heptares press-release, under the agreement Heptares would provide the GPCR antigen targets and Kymab would use their Kymouse platform to produce antibodies against the target.
Stay of injunction:
Kymab requested a stay of the injunction for certain activities.
Particularly, Kymab requested that it may be allowed to continue to supply and export Kymouse antibodies,
serum and antibody producing cells for the purpose of preparing and conducting pre-clinical and clinical trials and for the purpose of its collaborations with the the Gates foundation, IAVI and Heptares.
In support of Kymab's request, the Kymab's CEO Dr Chiswell submitted a witness statement describing Kymab's collaborations with the Gates foundation.
Dr Chiswell indicated that Kymab currently has three antibodies at clinical stage development with the potential to treat indications including inflammatory and autoimmune diseases and late stage cancer,
and that Kymab has a further series of antibodies at an earlier stage of development targeting the pertussis toxin and the malaria parasite,
for which they are "collaborating with a number of research institutes appointed by the Gates Foundation to develop novel antibody therapies for the developing world on a non-commercial basis".
・・・ 底値切りして反発を見送るうちに精神崩壊してるやつがいるなｗ
無理もない。含み損に耐えるより買い遅れて置いてかれる方がずっと辛いからな 大引けまでに高値を取らないと今日が天井になるわ
上値シコシコで明日から下値を模索する展開 >>70
おい、どうした？
ネガキャンやらねーのか？ >>135
昨日はお疲れさんしたー
87 名前：山師さん＠トレード中 (ﾜｯﾁｮｲ 220f-LHz9 [123.216.197.217])[sage] 投稿日：2018/06/11(月) 15:22:10.98 ID:EJ8wKrHk0 [2/2]
赤三兵か
明日、赤四兵になる確率は限りなく低い
だから今日買う奴は素人そのもの
林家ペーになるぞ >>70
このルサンチマンは一人何役でルサンチメンズやってたんだろうな
マジキチじゃんｗ 下がりもしないけど、上にも行かない
んでまた空売り軍団が揺らしたら暴落
あほくさ 意図的に上髭を付けて、それが転換線になるのだから
明日以降は下落する確率はより高くなったよ
上値シコシコどっぴゅんチャート
そして下がれば垂れ乳ババアは歓喜
好材料が無ければトレンドは↓
短期、中期、長期、全ての移動平均線が下向きなのだから お前らよく分かったなｗｗｗ
多少、外れたからと言って嘘は付かないぞ
逃げも隠れもしないで正々堂々と立ち向かう ｺﾂｺﾂこつコツコツｺﾂｺﾂｺﾂこつ どっかぁあーーーーーん。まだー。 笑う。 虎の威を借る狐
虎の威：空売り外資
狐：ルサンチメンズ >>149(ｱｳｱｳｶｰ Sa67-OWkY [182.251.244.8])
ルサンチメンズの実態（笑） >>87
あんたの"限りなく低い"なんざ、この程度のもんだったな
7000超えなかったからとか、別のネガティブ能書きを持ち出しますか？ あホルダーさん、今夜の晩ご飯も食欲出ますね。笑う。 >>120
あらら、そりゃ辛いですな。心中お察しします。
わたしの場合はバイオ投資は350万が4年で2700万になりました。 >>156
いいや俺はファンだは一切みない
テクニカルで判断して売買してるさかい
明日は今日の終値以上で始まり、高値を抜いて陽線で引けるならまだ期待はもてるさかい
以上 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。
成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。
Heptares will move to a New Research Facility (Steinmetz Building) at Cambridge (Granta Park) in August 2018. Place approximately 130 employees.
Heptares Zurich will be by mid-2018, the biology lab technician will be 70 -100%. Grow a team of protein biochemistry groups from the current 2 FTEs to 5 FTEs by 2020.
Heptares and Imperial College are trying to rapidly advance drug discovery and translation research with emphasis on new and existing multiple GPCR disease targets.
MiNA Therapeutics Step Up to the translation & innovation hub facility at Imperial College London Campus.
・・・
※SOSEI 2018年3月期決算：研究開発費4,818百万円(54％増加)97%は英国活動。毎年3つの新薬候補を発見することができるプラットフォーム構築。当社独自の化合物関連パイプラインが大幅に進展。自社開発品拡充。(5/10)
※SOSEI決算説明会：「戦略プランを着実に実行し2017年度は著しい進捗を達成」。事業は堅調に進捗。ビジネスモデル3つの柱：リスク低減及び収益機会の拡大。PLへの投資を継続。新たに6つの臨床試験予定：投与開始タイミング。 (5/10)
※SOSEI株式分割：基準日(2018/6/30)の株主名簿に記録された株主の所有普通株式1株につき4株の割合をもって分割。効力発生日(2018/7/１）。(5/10) ※SOSEI：決算期変更(事業年度の末日：毎年12/31)。(5/10)
※SMBC日興証券：そーせいグループ、R＆Dプロジェクト順調に推移、1：4の株式分割発表ポジティブ。(5/14)
※SOSE：定款の一部変更(事業年度末日・附則、議決権基準日、配当基準日等）、役員の異動(新たに3名の社外取締役増員)、公認会計士等の異動(有限責任監査法人トーマツ→新日本有限責任監査法人)。定時株主総会に付議。(5/16)
※個別株情報：みずほ証券は「提携型」から「自社創薬型」へビジネスモデルの転換点と判断。当面は赤字が継続するとみられるが、自社品上市が期待できる24.12期以降の成長スピードは、むしろ加速するとの見方。(5/21)
※SOSEI Presentation: "Sosei Group Corporation, UBS Global Healthcare Conference": Global operations and aspirations - aiming to build Japan’s first global biotech champion: Drive Global Growth Strategy. (5/21Presented, 5/22up)
※個別株情報：いちよし経済研究所では今18.12期に3つの開発品の臨床試験を自社で開始する予定と注目。中長期の利益予想を修正、導出品からの収入獲得への期待や、同社の新薬候補創出力に対する評価は変わらず。(5/22)
※ペプチドリーム：そーせいグループ株式会社との戦略的共同研究においてPAR2標的に対して高い親和性と選択性を有するペプチド・アンタゴニストを同定。わずか2カ月未満で同定することができました。(5/24)
※SOSEI：PAR2標的に対して高い親和性と選択性を有するペプチド・アンタゴニストを同定。ペプチドリーム社とのコラボレーションが順調に進展。現在は、臨床開発への進展を目指し、さらに本ペプチドの特性分析と最適化。(5/24) ※タイヨウ･パシフィック・パートナーズ：そーせいグループの発行済株式総数の5％超を取得し、実質調査ベースで第2位の株主になったと発表。「そーせいの経営陣と協働し、継続的な成長をサポートできることを楽しみにしています。」(6/3)
※SOSEI：役員の異動 (辞任)執行役副社長CFO：アンドリュー・オークリー(Autolus Therapeutics Limited, Senior Vice President and Chief Financial Officerへ)、暫定CFOにクリス・カーギルを任命。(6/4)
※SOSEI：第28回定時株主総会付議議案の一部取下げ(マイケル・ヘイデン氏を取締役候補者とすることを取り下げ)。(6/4)
※Pluristem: Announced that the top-line results of the company’s multinational Phase II clinical trial of PLX-PAD cells in the treatment of Intermittent Claudication (IC) will be released on June 12, 2018. (6/4)
※SOSEI：MiNA Therapeuticsが進行肝がん患者を対象とするMTL-CEBPAの初めてのヒト試験の初期結果を発表：正常肝機能および肝機能障害のある患者において良好な忍容性がみられた。血液検体の解析によりRNA活性機序を実証。薬効標的への作用を確認。(6/5)
※四季報先取り：そーせいグループ。【谷間】自社開発進捗順調で研究開発など先行費用増も重荷。赤字幅が急増。【自社開発加速】18年、19年ともレビー小体型認知症薬など年三つの治験予定。英バイオ株追加取得の判断は18年下期に。(6/6)
※Heptares_HP: Download Corporate Presentation: "2018.06.08 Corporate Presentation (Sosei Group Corporation Corporate Presentation June 2018)". Changed: Andrew Oakley, CFO→Chris Cargill, Interim CFO. (6/8up)
※Heptares: Congratulations to our founder Richard Henderson, named a Companion of Honour in the Queen's Birthday Honours list.. (6/8)
・・・
※Innovation in Research: "Cells, Mars and the Bomb": Karine Kleinhaus, Ph.D. Divisional Vice President, North America Pluristem. (Today 13:20 Presenting)
※NovAlix Biophysics in Drug Discovery 2018: "Structural Insight into Allosteric Modulation of GPCRs": Miles Congreve, Heptares. (6/14 15:10)
※四季報(2018年3集夏号)：6月15日発売(更新)。
※EHA: "MTL-CEBPA, a Small Activating RNA for Intravenous Administration to Enhance C/EBPΑ Expression in Patients with Liver Cancer Shows Potential Use in Neutropenia": Choon Ping Tan, MiNA Therapeutics. (6/16 17:30)
※Biotech Outsourcing Strategies 2018: Attending-Companies: Heptares Therapeutics, CMC Projects Manager. (6/19-20)
※SOSEI 第28回定時株主総会：(6月22日 10:00 グランドアーク半蔵門4階 富士の間)
※SOSEI個人投資家説明会：(6月25日：名古屋会場10:00-11:30、大阪会場15:30-17:00)
・・・ ※SOSEIの成長相場の動向：[株式4分割：基準日2018/6/30・効力発生日2018/7/１]。
2010/12/30 (終値_1350) ・(2010/10/15※最安値_650、2010/12/27最高値_1748)
2011/12/30 (終値_1271) ・(2011/3/15※最安値__693、2011/6/30最高値_1680)
2012/12/28 (終値_2087) ・(2012/6/6※最安値__950、2012/9/7最高値_2967)
2013/12/30 (終値_4315) ・(2013/1/4※最安値_2050、2013/5/7最高値_6100)
2014/_4/25 (終値_2058) 売残高36200 買残高 1053200 ・(2014/4/22最安値_1854)※[成長回収期の入口]ステージへ
2015/_2/20 (終値_3780) 売残高14200 買残高 1530800 ・(2015/3/16最安値_2851)※Heptares [成功の序章ステージ]
2015/10/30 (終値_4320) 売残高11400 買残高 2217900 ・(2015/9/24安値_3550)※米国承認[次なる飛躍ステージへ]
2015/11/27 (終値_6360) 売残高 14800 買残高 2552500 ・(2015/11/30終値_6060: Pfizer)※[上抜け圏へ]
2016/_4/25 (終値23230) 売残高39800 買残高 3404900 ・(2016/5/9最高値26180)※Allergan[強気相場]
2016/_6/24 (終値14720) 売残高10500 買残高 2486100 ・(2016/6/24安値12960)※[強気相場解除]→※[時間軸での調整局面へ]
2017/_1/_6 (終値14030) 売残高__300 買残高 2907100 ・(2017/2/13安値12400)※[強気相場解除後の時間軸調整は順調に推移]
2017/_3/31 (終値10880) 売残高_5600 買残高 2621800 ・(2017/4/4安値10280)※[振るい場・拾い場へ]
2017/_9/_8 (終値_8700) 売残高_1900 買残高 2037800 ・(2017/9/6最安値_8590)※[拾い場も順調に推移]
2018/_1/26 (終値12210) 売残高__900 買残高 1429100 ・(1/22安値10960)※[振るいも順調に推移] 2018/_3/_9 (終値_9510) 売残高10500 買残高 1794400(_-60200) ・(3/5安値_8780)※[悪地合いにて再びの拾い場へ]
2018/_3/16 (終値_9070) 売残高13500 買残高 2019900(+225500) ・(3/16安値_9070)
2018/_3/23 (終値_8590) 売残高14100 買残高 2046500(_+26600) ・(3/23安値_8580)
2018/_3/30 (終値_8820) 売残高14400 買残高 2028000(_-18500) ・(3/26安値_8320)
2018/_4/_6 (終値_8810) 売残高17000 買残高 1981500(_-46500) ・(4/3安値_8550)
2018/_4/13 (終値_7840) 売残高15400 買残高 2080200(_+98700) ・(4/13安値_7770)
2018/_4/20 (終値_7280) 売残高15100 買残高 2115200(_+35000) ・(4/20安値_7260)
2018/_4/27 (終値_7580) 売残高17700 買残高 2113400(__-1800) ・(4/23安値_7210)
2018/_5/11 (終値_7040) 売残高21200 買残高 2099200(_-14200) ・(5/11安値_6660)※(5/11)空売り価格規制トリガー抵触
2018/_5/18 (終値_7600) 売残高19700 買残高 2047200(_-52000) ・(5/14安値_6980)
2018/_5/25 (終値_7170) 売残高19500 買残高 2091100(_+43900) ・(5/25安値_7120)
2018/_6/_1 (終値_7350) 売残高23000 買残高 2081000(_-10100) ・(5/29安値_6780)
2018/_6/_8 (終値_6800) 売残高26200 買残高 2178700(_+97700)※6/12up ・(6/7最安値_6470)※[年初来安値] ※(6/5)空売り価格規制トリガー抵触
2018/_6/11 (終値_6890) 5日線乖離(+2.01％) 25日線乖離(-4.86％) 75日線乖離(-15.63％) 200日線乖離(-27.64％) (安値_6810)
2018/_6/12 (終値_6950) 5日線乖離(+2.78％) 25日線乖離(-3.68％) 75日線乖離(-14.49％) 200日線乖離(-26.90％) (安値_6940) ※Technical Analysis Charts (Week)：
ttps://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=980&Height=650&Cycle=WEEK1&Duration=9999&TopMargin=10&Render=Candle&ShowName=0&Company=4Traders_us
※Technical Analysis Charts (Day)：
ttp://www.4-traders.com/SOSEI-GROUP-CORPORATION-6814799/charts/&applet_mode=statique
更なる成長の黎明期にて、強気相場解除後の時間軸での調整の終盤(拾い場)は、上抜け圏で順調に推移。笑。
中長期成長戦略(R&D・PL等の拡充・進捗)も順調・着実な進展で、次なる展開・進捗が楽しみです。笑。
予定通りの拾い場は順調推移。決算通過・株式分割、今回も面白くなりましたね。笑。 ・・・
※Pluristem: Announced that the top-line results of the company’s multinational Phase II clinical trial of PLX-PAD cells in the treatment of Intermittent Claudication (IC) will be released on June 12, 2018. (6/4)
↓
※Pluristem Reports: Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study. (6/12)
Tue June 12, 2018 6:00 AM|GlobeNewswire|About: PSTI
・PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility.
・Study validates the design of Pluristem’s ongoing Pivotal Phase III study in Critical Limb Ischemia (CLI)
HAIFA, Israel, June 12, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products,
today announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC).
PLX-PAD treatment reduced Incidence of revascularization and improved patients’ mobility. Study results also validate the design of Pluristem’s ongoing Pivotal Phase III study in CLI,
a more severe stage of peripheral arterial disease (PAD) and confirm Pluristem’s proprietary Bio-Therapeutic approach.
Pluristem's Phase II IC study was designed to evaluate the safety, efficacy and optimal dosing regimen for PLX-PAD cells in patients with IC, Rutherford categories 2-3.
Enrollment took place at 28 clinical sites in the U.S., Germany, South Korea and Israel.
The 172 patients in the study were randomized into four treatment groups: two administrations of 300 million PLX-PAD cells (“main efficacy group”); two administrations of 150 million PLX-PAD cells;
two administrations of placebo; or one administration of 300 million PLX-PAD cells followed by placebo.
In each of these study arms, the two administrations were given intramuscularly (IM), 3 months apart.
The primary efficacy endpoint was the change from baseline in maximal walking distance (MWD) at 52 weeks compared to placebo.
The key secondary endpoint was the change from baseline in MWD at 52 weeks compared to placebo, in patients treated with 2 doses of PLX-PAD originating from different placentas (Pluristem’s proprietary Bio-Therapeutic approach).
Other endpoints included risk of revascularization and other hemodynamic and clinical outcome measures. Top Line Results:
・Patients treated with 2 administrations of 300 million PLX-PAD cells showed statistically significant improvement (p=0.0008) in MWD as compared to baseline at 52 weeks.
・Key primary efficacy endpoint, improvement in MWD as compared to placebo, in analysis by country, showed best results with statistically significant improvement (effect size= 51.1%, p=0.015) in U.S patients (n=73) treated with 2 administrations of 300 million PLX-PAD cells.
・Key secondary efficacy endpoint, improvement in MWD following administration of 2 doses of 300 million PLX-PAD cells originating from different placentas, showed statistically significant improvement at 52 weeks (effect size= 42.0%, p=0.043) as compared to placebo.
・These patients also demonstrated a statistically significant improvement (effect size= 83%, p=0.0007) in MWD at 52 weeks as compared to baseline.
・Revascularization risk was reduced by 49% (Hazard ratio = 0.51) in the main efficacy group at week 65. Patients receiving 2 administrations of PLX-PAD cells originating from different placentas were “revasc-free” (no revascularization events) at week 65.
・IM administration of PLX-PAD cells was safe and well tolerated.
Validation of study design in ongoing Pivotal Phase III study in Critical Limb Ischemia (CLI):
・Dose confirmation- Study results demonstrated dose of 300 million PLX-PAD cells as the optimal dose for treatment of PAD
・Two administrations of 300 million PLX-PAD cells demonstrated a statistically significant superior effect (p=0.0331) compared to a single administration of 300 million PLX-PAD cells in MWD at week 52, suggesting that in chronic indications such as PAD a second treatment may be required to significantly improve the clinical outcome.
・Pluristem’s proprietary Bio-Therapeutic approach of using cells originating from different placentas for each administration, as implemented in the CLI pivotal Phase III clinical study, was shown to generate a superior therapeutic effect. “We are highly encouraged by the results seen in the study.
The option of treating peripheral artery diseases like IC and CLI through IM injections of PLX-PAD cells is promising, and an important outcome, demonstrating the potential ability to implement regenerative medicine advanced technologies in cardiovascular diseases.
We look forward to the CLI pivotal study results that may demonstrate the ability of Pluristem’s cell therapy to improve patient outcomes and create economic benefits for the healthcare systems,”
stated Dr. Manesh Patel, Chief of the Division of Cardiology at Duke University Health System, and the lead principle investigator (PI) for the U.S. Phase II IC study.
“These promising results demonstrate a clinically meaningful treatment effect. Finding a non-surgical medical solution for PAD, especially in patients who are unsuitable for revascularization, has proven to be one of the biggest medical challenges in recent years.
These study results are highly encouraging and suggest that PLX-PAD cells may be the answer for both PAD patients and physicians seeking effective medical solutions,”
commented Prof. Norbert Weiss, MD, Director of the Vascular Center at the Technical University of Dresden, Germany, and the lead PI for the European Phase II IC study.
“We are very pleased with the study results that may bring hope to millions of patients worldwide suffering from peripheral artery diseases,” stated Pluristem Chairman and Co-CEO Zami Aberman.
“These results suggest that PLX-PAD cells may be efficacious in the treatment of PAD and could significantly reduce the need for invasive procedures in these patients.
Furthermore, these results provide important validation to our ongoing pivotal Phase III study in CLI in terms of dose selection,
dual-dosing administration regimen and the superiority of our proprietary Bio-Therapeutic approach we have developed in the last few years of using different placentas when more than one treatment is required.
The unique PLX platform and manufacturing processes we developed enable us to confirm donor-to-donor and batch-to-batch comparability and achieve optimal clinical benefits.” About Peripheral Artery Diseases (PAD):
Peripheral Arterial Disease (PAD) is caused by fatty deposits in leg arteries that obstruct blood flow. Risk factors include smoking, diabetes, heavy weight, cardiovascular problems and hypertension.
An earlier stage of PAD is Intermittent Claudication (IC) with symptoms of leg pain and weakness brought on by exercise, with resolution of the symptoms following rest.
IC can progress to Critical Limb Ischemia (CLI) when patients suffer from severe pain at rest, skin wounds, tissue necrosis and poor quality of life with a high risk of leg amputation and death.
PAD affects 4-12% of people aged 55-70 years and 15-20% of people aged over 70 years. The frequency of lower extremity artery disease is strongly age-related, rising steeply after 50 years of age.
PAD afflicts about 20 million U.S. citizens, 28 million Western Europeans and 42 to 60 million Chinese citizens.
Pluristem’s Phase III study in Critical Limb Ischemia (CLI), was cleared by the U.S Food and Drug Administration (FDA) and European Medicines Agency (EMA) and is recruiting patients (n=246) in the U.S. and Europe.
About Pluristem Therapeutics:
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products.
The Company has reported robust clinical study data in multiple indications for its patented PLX cells and is entering late-stage studies in several indications.
PLX cell products release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders, and radiation damage.
The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching.
Pluristem has a strong intellectual property position; Company-owned and operated, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team. ※HeptaresTL 43分前：Miles Congreve Talk: "Structural Insight into Allosteric Modulation of GPCRs"; 5th NovAliX Conference / Boston, USA - June 13-15.
・6/14 15:10 Presenting ※International Journal of Chronic Obstructive Pulmonary Disease: Review: "Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease". (6/12)
Published: 12 June 2018. (Volume 13, 2018: Pages 1873-1888)
Abstract:
Long-acting muscarinic antagonists (LAMAs), along with long-acting β2-agonists (LABAs), are the mainstay for treatment of patients with COPD.
Glycopyrrolate, or glycopyrronium bromide, like other LAMAs, inhibits parasympathetic nerve impulses by selectively blocking the binding of acetylcholine to muscarinic receptors.
Glycopyrrolate is unusual in that it preferentially binds to M3 over M2 muscarinic receptors, thereby specifically targeting the primary muscarinic receptor responsible for bronchoconstriction occurring in COPD.
Inhaled glycopyrrolate is slowly absorbed from the lungs and rapidly eliminated from the bloodstream, most likely by renal excretion in its unmetabolized form, limiting the potential for systemic adverse events.
Inhaled glycopyrrolate is a fast-acting, efficacious treatment option for patients with moderate–severe COPD.
It improves lung function, reduces the risk of exacerbations, and alleviates the symptoms of breathlessness, which in turn may explain the improvement seen in patients’ quality of life.
Inhaled formulations containing glycopyrrolate are well tolerated, and despite being an anticholinergic, few cardiovascular-related events have been reported.
Inhaled glycopyrrolate is thus of value as both monotherapy and in combination with other classes of medication for maintenance treatment of COPD.
This review covers the mechanism of action of inhaled glycopyrrolate, including its pharmacokinetic, pharmacodynamic, and safety profiles, and effects on mucus secretion.
It also discusses the use of inhaled glycopyrrolate in the treatment of COPD, as monotherapy and in fixed-dose combinations with LABAs and inhaled corticosteroid–LABAs, including a triple therapy recently approved in Europe.
ttps://www.dovepress.com/getfile.php?fileID=42573 ※Pluristem 12分前："These study results are highly encouraging and suggest that PLX-PAD cells may be the answer for both PAD patients and physicians seeking effective medical solutions". (6/12)
・Top-Line Results from Its Multinational Phase II Intermittent Claudication Study: PLX-PAD treatment reduced risk of revascularization and improved patients’ mobility. Study validates the design of Pluristem’s ongoing Pivotal Phase III study in CLI. 株主総会まで7営業日
株主総会で話すことほぼないな
また2017年4月のマイルストンいくつかもらったことを話してドヤるのか
またm1とm2m3の比較グラフでm1の選択制が～の比較グラフ見せられるの？
もう10回はみたからとっとと治験すすめろ おまえのクソ同然の完全に終わってる人生と違って開発状況は日々進捗してるんだよ M1アルツもM4も現在治験中。焦るなよ。
その内にkymabとの進展やM1DLBの治験開始も来るし、
ファイザーとの現状も見えてくるから。 なんかゲームアプリの会社とでも勘違いしてるんじゃなかろうか
待つことが出来ないならバイオに投資するなよ クソニートか死にかけのジジイだから暇なんだろ
毎日株価ボードの点滅だけを見続けるだけ 一日の含み損も耐えれない連中しかいないんだよここは まだチャートが反転してないからな
今買いで持ってる奴は100％リバ狙いのギャンブラー
長期投資の人はまだ買えない 今日も、あホルダーさん歓喜のガッツポーズ状態。笑う。 ファイザーの買値基準で下がりすぎてるから入ったけど甘かったかね。 7000ぐらいがもう戻り天井か
ドンドンと天井がずり落ちてるな ラオクオリア安値から約40％上昇
そーせい安値から7.7％上昇
垂れ乳ババアチャートの威力は凄まじい もしラクオリアみたいに安値から約40％も上昇したら
今頃、そーせいさんは9058円なんですわ・・
この垂れ乳具合はそそられる
熟女好きにはたまらないだろ？ ここも分割後1000円になれば1400円までは早いだろ！ 曙ブレーキは糞決算でダダ下げでも世界初ウンチャラで309円S高（+34.93％
そーせいの垂れ乳ババアも少しはバストアップたのむわ
重力に勝てよ 垂れ乳ババアのバキュームフェラの吸引力には勝てないのか？
マジで9000円でええから買収されちまえよ ■ このスレッドは過去ログ倉庫に格納されています
